GH vs. GTH, BNR, PSNL, NTRA, EXAS, RDNT, FTRE, VCYT, VRDN, and CDNA
Should you be buying Guardant Health stock or one of its competitors? The main competitors of Guardant Health include Genetron (GTH), Burning Rock Biotech (BNR), Personalis (PSNL), Natera (NTRA), Exact Sciences (EXAS), RadNet (RDNT), Fortrea (FTRE), Veracyte (VCYT), Viridian Therapeutics (VRDN), and CareDx (CDNA).
Guardant Health (NASDAQ:GH) and Genetron (NASDAQ:GTH) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, community ranking, valuation, analyst recommendations and dividends.
Guardant Health received 263 more outperform votes than Genetron when rated by MarketBeat users. Likewise, 68.83% of users gave Guardant Health an outperform vote while only 33.33% of users gave Genetron an outperform vote.
92.6% of Guardant Health shares are owned by institutional investors. Comparatively, 10.7% of Genetron shares are owned by institutional investors. 5.5% of Guardant Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Guardant Health presently has a consensus target price of $36.60, suggesting a potential upside of 35.06%. Given Guardant Health's higher possible upside, analysts plainly believe Guardant Health is more favorable than Genetron.
Genetron has a net margin of 0.00% compared to Guardant Health's net margin of -76.34%. Genetron's return on equity of 0.00% beat Guardant Health's return on equity.
Genetron has lower revenue, but higher earnings than Guardant Health.
In the previous week, Guardant Health had 12 more articles in the media than Genetron. MarketBeat recorded 12 mentions for Guardant Health and 0 mentions for Genetron. Guardant Health's average media sentiment score of 0.23 beat Genetron's score of 0.00 indicating that Guardant Health is being referred to more favorably in the media.
Guardant Health has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, Genetron has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.
Summary
Guardant Health beats Genetron on 11 of the 15 factors compared between the two stocks.
Get Guardant Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for GH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Guardant Health Competitors List
Related Companies and Tools
